Contrast-enhanced ultrasound is performed with injections of microbubble contrast agents such as Levovist® and Sonazoied®. Contrast-enhanced diagnostic imaging rapidly developed in the 1980s by the introduction of intra-arterial CO2 injection1). In September 1999, Levovist®, a microbubble contrast agent, became available commercially in Japan. Contrast-enhanced imaging using Levovist® is based on the fact that microbubbles are readily disrupted by exposure to ultrasound. This causes the microbubbles to produce a nonlinear ultrasound signal as they disappear. Specialized imaging modalities such as harmonic imaging are used to visualize nonlinear signal properties of microbubbles effectively. Contrast-enhanced diagnostic imaging techniques have become highly influential in the diagnosis and treatment of liver, pancreas and gallbladder tumors. This report outlines the usefulness of Levovist® imaging and its effectiveness in the diagnostic differentiation of tumors in the liver, pancreas and gallbladder. A next-generation contrast agent, Sonazoid®, also became available in January 2007 with insurance reimbursement. Currently, insurance reimbursement applies only when Sonazoid® is used for diagnosis of tumorous diseases of the liver. Imaging data using Sonazoid® obtained from pancreatic tumor cases are also described in this report.